Technology
Health
Biotechnology

Palatin Technologies

$1.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (1.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PTN and other stocks, options, ETFs, and crypto commission-free!

About

Palatin Technologies, Inc., also called Palatin Technologies, is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). Read More The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Employees
19
Headquarters
Cranbury, New Jersey
Founded
1986
Market Cap
205.09M
Price-Earnings Ratio
245.85
Dividend Yield
0.00
Average Volume
1.41M
High Today
$1.01
Low Today
$0.9921
Open Price
$0.9922
Volume
190.64K
52 Week High
$1.59
52 Week Low
$0.59

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

MarketBeatMar 9

Stock Price, News, & Analysis for Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, ...

199
Yahoo FinanceFeb 26

Analysis: Positioning to Benefit within Weatherford International, NiSource, Palatin Technologies, Astronics, MaxLinear, and FutureFuel — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Weatherford International PLC (WFT), NiSource, Inc (NI), Palatin Technologies, Inc. (PTN), Astronics Corporation (ATRO), MaxLinear, Inc (MXL), and FutureFuel Corp. (FF), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. C...

4,756
Seeking AlphaFeb 21

Palatin: What To Do After The Share Pullback?

Palatin Technologies (PTN) has successfully developed bremelanotide, a drug that deals with the problem of hypoactive sexual desire disorder (HSDD) in women.

1,408

Earnings

-$0.04
-$0.00
$0.03
$0.07
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 15, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.